Hikma Pharmaceuticals PLC at JPMorgan Healthcare Conference Transcript
Good morning. I'm James Gordon, JPMorgan European pharma biotech analyst. And today, I've got the pleasure of introducing the Hikma presentation and we're going to hear from Hikma's new CEO, Riad Mishlawi. Thanks a lot for joining us today, Riad, and look forward to the presentation.
Thank you. All right. I had to project my voice because I'm too tall for the microphone. So good morning. Thank you very much for coming here. My name is Riad Mishlawi. Very happy to be here today. This is my first time presenting at JPMorgan in the conference.
As James has said, I've been newly appointed CEO. I've been in this role for 133 days, but who's counting? Previously, I was the President of the injectables in Hikma for quite some time. Today, I'd like to give you a brief overview of the business and our recent performance, and then set out how we are going to look at the future and our various levers for continued growth.
Just a couple of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |